文献速递肝肾功能剂量调整治疗药物监测与药物基因组学抗菌药物管理

黏菌素临床药代动力学与药效学综述

Clinical Pharmacokinetics and Pharmacodynamics of Colistin.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

本文综述黏菌素(多黏菌素E)的药代动力学与药效学特征。黏菌素为治疗多重耐药革兰阴性菌感染的最后防线药物,静脉给药用前药黏菌素甲磺酸钠(CMS),口服给药用硫酸黏菌素。因黏菌素药代动力学变异大且治疗窗窄,建议进行治疗药物监测;肾功能影响CMS清除,需据肾功能调整剂量。

要点

  • 黏菌素药代动力学变异大、治疗窗窄,建议进行治疗药物监测。
  • 静脉用CMS部分经肾清除,给药方案需根据患者肾功能调整。
  • 使用负荷剂量可能减少耐药发生,但联合用药似乎也是必要的。

核心结论

  • 黏菌素药代动力学变异大且治疗窗窄,建议进行治疗药物监测。
  • CMS部分经肾清除,给药方案需根据患者肾功能调整。
  • 使用负荷剂量可能减少耐药出现,但联合用药似乎也是必要的。

研究设计与样本

  • 本文为综述,汇总黏菌素药代动力学与药效学的更新信息。

主要发现

  • 黏菌素因分子量大且在生理pH下带阳离子,难以通过生理膜,主要分布于细胞外液。
  • 黏菌素肾清除率很低,但CMS部分经肾消除,故给药方案需适应患者肾功能。
  • 细菌对黏菌素耐药在全球随临床与兽医使用增加而上升,近期在动物和人类中描述了质粒介导的耐药机制MCR-1。
  • 体外实验中细菌暴露于黏菌素后迅速产生多种耐药机制。

临床怎么用

  • 静脉使用CMS时根据患者肾功能调整给药方案。
  • 对黏菌素进行治疗药物监测以应对药代动力学变异大和治疗窗窄的问题。
  • 考虑使用负荷剂量并评估联合用药以减少耐药出现。

局限性

  • 黏菌素可与实验室材料结合,带来许多实验问题,使相关研究较为棘手。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this review, we provide an updated summary on colistin pharmacokinetics and pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment for infections caused by multidrug-resistant Gram-negative bacteria. Colistin is a decapeptide administered either as a prodrug, colistin methanesulfonate (CMS), when used intravenously, or as colistin sulfate when used orally. Because colistin binds to laboratory materials, many experimental issues are raised and studies on colistin can be tricky. Due to its large molecular weight and its cationic properties at physiological pH, colistin passes through physiological membranes poorly and is mainly distributed within the extracellular space. Renal clearance of colistin is very low, but the dosing regimen should be adapted to the renal function of the patient because CMS is partly eliminated by the kidney. Therapeutic drug monitoring of colistin is warranted because the pharmacokinetics of colistin are very variable, and because its therapeutic window is narrow. Resistance of bacteria to colistin is increasing worldwide in parallel to its clinical and veterinary uses and a plasmid-mediated resistance mechanism (MCR-1) was recently described in animals and humans. In vitro, bacteria develop various resistance mechanisms rapidly when exposed to colistin. The use of a loading dose might reduce the emergence of resistance but the use of colistin in combination also seems necessary.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Grégoire N, Aranzana-Climent V, Magréault S, et al. Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin Pharmacokinet. 2017. PMID: 28550595. doi:10.1007/s40262-017-0561-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。